Carl Zeiss Meditec AG ADR CZMWY
Morningstar’s Analysis
1-Star Price
PREMIUM
5-Star Price
PREMIUM
Economic Moat
PREMIUM
There is no one analyst in which a Quantitative Star Rating and Fair Value Estimate is attributed to; however, Mr. Lee Davidson, Head of Quantitative Research for Morningstar, Inc., is responsible for overseeing the methodology that supports the quantitative fair value. As an employee of Morningstar, Inc., Mr. Davidson is guided by Morningstar, Inc.'s Code of Ethics and Personal Securities Trading Policy in carrying out his responsibilities. For information regarding Conflicts of Interests, click here .
Morningstar Quantitative ratings for equities (denoted on this page by) are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies withratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating. Click here for more on how to use these ratings.
Company Profile
Carl Zeiss Meditec is a Jena, Germany-based manufacturer of ophthalmic devices, such as intraocular lenses, diagnostic equipment, and refractive laser systems, along with optical equipment for microsurgical applications such as neurosurgery. The company now reports in two primary segments, ophthalmic devices (74% of fiscal 2020 revenue) and microsurgery (26%). From a geographic perspective, the firm has a balanced mix of global sales, with 30% derived from Europe, the Middle East, and Africa, 32% from the Americas, and 38% from Asia-Pacific.